We investigated the effects of polymyxin B (PMB), an antibiotic that binds to endotoxins, on the uptake and degradation of low density lipoproteins (LDLs) in HepG2 cells, a highly differentiated human hepatoma cell line. The results showed that PMB very effectively enhanced the binding, intemalization, and degradation of LDL in HepG2 cells. The PMB-mediated enhancement of LDL uptake was not dependent on the LDL receptor-mediated pathway, as blockage of the LDL receptor by use of a monoclonal anti-LDL receptor antibody had no effect on the PMB-mediated cellular processing of LDL and PMB-mediated enhancement of LDL uptake did not cause an increase in cholesterol esterification. In addition, chloroquine and colchicine, which inhibit lysosomal degradation and cellular endocytosis, respectively, diminished PMB-enhanced degradation of LDL, indicating that PMB mediates uptake through a pathway similar to the LDL receptor-mediated pathway. The PMB-mediated uptake of LDL was sensitive to treatment with phospholipase C and pronase and was dependent on the presence of Ca 2+ . PMB caused similar changes in human skin flbroblasts, bovine smooth muscle cells, and bovine endothelial cells, which suggests that PMB-enhanced LDL uptake is a general cellular phenomenon. Our results thus indicate that PMB increases cellular catabolism of LDL through an endocytotic pathway not involving the LDL receptors. ( 1 In addition to its antimicrobial activity, PMB has potent antiendotoxin properties.
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We investigated the effects of polymyxin B (PMB), an antibiotic that binds to endotoxins, on the uptake and degradation of low density lipoproteins (LDLs) in HepG2 cells, a highly differentiated human hepatoma cell line. The results showed that PMB very effectively enhanced the binding, intemalization, and degradation of LDL in HepG2 cells. The PMB-mediated enhancement of LDL uptake was not dependent on the LDL receptor-mediated pathway, as blockage of the LDL receptor by use of a monoclonal anti-LDL receptor antibody had no effect on the PMB-mediated cellular processing of LDL and PMB-mediated enhancement of LDL uptake did not cause an increase in cholesterol esterification. In addition, chloroquine and colchicine, which inhibit lysosomal degradation and cellular endocytosis, respectively, diminished PMB-enhanced degradation of LDL, indicating that PMB mediates uptake through a pathway similar to the LDL receptor-mediated pathway. The PMB-mediated uptake of LDL was sensitive to treatment with phospholipase C and pronase and was dependent on the presence of Ca 2+ . PMB caused similar changes in human skin flbroblasts, bovine smooth muscle cells, and bovine endothelial cells, which suggests that PMB-enhanced LDL uptake is a general cellular phenomenon. Our results thus indicate that PMB increases cellular catabolism of LDL through an endocytotic pathway not involving the LDL receptors. otic produced by various strains of Bacillus pofyrnyxa, an aerobic spore-forming rod found in soil. 1 In addition to its antimicrobial activity, PMB has potent antiendotoxin properties. 2 Its clinical use, however, is limited by its neurotoxicity and nephrotoxicity. When we studied the interactions between endotoxins, lipoproteins,. and cells, we accidentally discovered that PMB very effectively increased the uptake and degradation of low density lipoproteins (LDLs) in hepatic and extrahepatic cells. LDL, the main cholesterolcarrying lipoprotein in plasma, is associated with atherosclerosis when present in high plasma concentrations. 3 Enhanced catabolism of LDL by the liver decreases plasma LDL concentrations. Thus, to study the regulation of plasma concentrations of LDL, one must focus on liver catabolism. In this article, we explore the effects of PMB on the cellular uptake and degradation of LDL in HepG2 cells, a highly differentiated human hepatQma cell line. The study shows that PMB effectively increases LDL binding, internalization, and degradation by an endocytotic non-LDL receptor-mediated pathway.
Bovine smooth muscle cells (SMCs) were grown from explanted segments of the thoracic aorta according to Stavenow and Tejler. 5 The cells were grown under the same conditions as used in the FB cultures described above.
Bovine endothelial cells (ECs) from the thoracic aorta were established 6 and maintained in Dulbecco's modified Eagle's medium/Ham's F12 medium (1:5, vol/vol) containing 10% FCS and 0.1 mg/ml gentamicin in gelatin-coated flasks at 37°C in a humidified 5% CO 2 atmosphere.
The cells, i.e., human FBs, bovine SMCs, and bovine ECs, from passages two to three were used in the present experiments.
To initiate the experiments, cells were trypsinized with 0.05% trypsin/0.02% EDTA (Life Technologies Ltd.), plated into 35-mm plastic petri dishes (NUNCLON), and grown in 2 ml medium containing 10% FCS. The culture medium was routinely changed every 2-3 days. The experiments started when the cells became subconfluent, i.e., when they covered approximately two thirds of the bottom of the dish. The medium was changed to 1 ml medium containing 0.5% human serum albumin (HSA) without FCS for an LDL binding, uptake, and degradation assay.
Lipoprotein Isolation and Labeling
To prepare LDLs, blood was drawn from normocholesterolemic subjects into EDTA-containing Vacutainer tubes (100x16 mm, Becton Dickinson, Rutherford, N.J.). Immediately, thimerosal (sodium ethylmercurithiosalicylate; Sigma) was added to a final concentration of 25 fiM to inhibit proteolytic activity. LDL was isolated from plasma by sequential preparative ultracentrifugation 7 using an LKB 2331 Ultrospin 70 ultracentrifuge with the SRP 70AT rotor. A narrow density range (1.034-1.054 kg/1) was used in the experiments to minimize contamination of LDL with apolipoprotein E.
LDL was iodinated with 125 I by the iodine monochloride method 8 as modified for lipoproteins. 9 Unbound 125 I was removed by chromatography on a Sephadex G-25 column PD-10 (Pharmacia, Uppsala, Sweden) followed by extensive dialysis against 0.15 M NaCl with 1 mM EDTA, pH 7.4. The specific activity of the LDL was between 150 and 400 cpm/ng LDL protein.
Low Density Lipoprotein Binding Assay
The binding of LDL to HepG2 cells was performed at 4°C and 37 D C. At 4°C before the binding experiment began, the cells were washed twice with 1 ml phosphatebuffered saline (PBS) containing 0.2% bovine serum albumin (BSA). One milliliter ice-cold RPMI-1640 containing 0.5% HSA (fraction V; Sigma) was then added to each dish. The cells were thereafter precooled for 20 minutes in a 4°C cold room. After that, 125 I-LDL (5.33 /xg/ml medium) was added to each dish for a 2-hour incubation at 4°C. After the incubation the cells were washed twice with 1 ml ice-cold PBS containing 0.2% BSA and subsequently twice with PBS without BSA and then scraped into 1 ml 0.5 M NaOH for measurement of radioactivity in a gamma counter (LKB model 1271 automatic gamma counter) and for cell protein determination.
The binding of LDL to HepG2 cells was also examined at 37°C. Subconfluent cells were used. The growth medium was changed to 1 ml RPMI-1640 containing 0.5% HSA with 125 I-LDL (5.33 /xg LDL protein/ml medium) for a 4-hour incubation at 37°C. Then the medium was removed for a degradation assay as described below. The cells were washed twice with PBS containing 0.2% BSA and once with PBS. To determine the amount of I25 I-LDL bound to the cell surface, each dish received 1 ml PBS containing 10 /ig/ml trypsin for a further 30-minute incubation at 37°C. The radioactivity released by trypsin is the measure of bound LDL, and that remaining with the cells is internalized LDL.
Low Density Lipoprotein Uptake and Degradation Assay
Experiments were started when the cells were subconfluent. At the start of the experiment, the growth medium was changed to 1 ml medium with 0.5% HSA.
125
I-LDL was then added to the dishes. The cells were put in an incubator and kept at 37°C, usually for 4 or 24 hours, with the indicated exceptions. After incubation, the cells were washed with 1 ml cold PBS three times and scraped into 1 ml 0.5 M NaOH for a subsequent measurement of gamma radioactivity, referred to as the uptake by the cells (the sum of bound and internalized I radioactivity in the medium. 10 The results are expressed as nanograms LDL protein taken up or degraded per milligram cell protein.
Cholesterol Esterification Assay
HepG2 cells were grown in 2 ml RPMI-1640 supplemented with 10% FCS until they were subconfluent. Then the medium was changed to 1 ml RPMI-1640 containing 0.5% HSA (pH 7.4) and unlabeled LDL (100 fig protein/ (1.6xlO 6 dpm/ml medium) was added to the cells for a further 4-hour incubation at 37°C. After the 4-hour incubation, the medium was aspirated and the cells were washed three times with 1 ml cold PBS. The cellular lipids were then extracted with chloroform/ methanol (1:2, vol/vol). 12 The chloroform phase was dried under nitrogen, and the lipids were dissolved in 200 yu. 1 petroleum ether and spotted on a silica gel G 60 thin-layer chromatography plate (E. Merck, Darmstadt, FRG) and separated with petroleum ether/diethyl ether/acetic acid (80:20:1, vol/vol/vol). 13 The cholesteryl ester spots were identified after exposure to iodine vapor (Sigma) and compared with an internal standard (cholesteryl oleate, Sigma), cut from the plate, and counted in 10 ml Luma Gel (Lumac, The Netherlands) in a beta counter (Packard model 300 CD liquid scintillation spectrometer). The results are expressed as disintegrations per minute incorporated per milligram cell protein.
Anti-Low Density Lipoprotein Receptor Antibody
This antibody blocks LDL receptor-mediated uptake of LDL in cultured human FBs, as described by Beisiegel et al. 14 The dilution and freezing protocol recommended by the manufacturer was followed. 
I-LDL (5.33 ug LDL protein/ml medium) with (100 figI ml medium) or without PMB was added to the dishes for a binding assay as described in "Methods." Values are mean of two dishes.

Protein Determination
The protein contents of the cells and LDL were determined with the Lowry method 15 using HSA as the standard.
Statistical Analyses
Experimental results were analyzed for their statistical significance by Student's t test. A probability value less than 0.05 was considered significant.
Results
Polymyxin B Enhances Low Density Lipoprotein Binding, Internalization, and Degradation in HepG2 Cells
Because internalization of ligands by receptor-mediated endocytosis is inhibited at 4°C, binding of LDL to HepG2 cells was examined at this temperature. The binding of LDL to HepG2 cells at 4°C in the presence of 100 /xg PMB/ml medium was 4.7 times (/?<0.005) higher than that in the absence of PMB ( Figure 1 ). The binding, internalization, and subsequent degradation of LDL in HepG2 cells at 37°C in the presence of 100 fig PMB/ml medium were also much higher than those in the absence of PMB. PMB caused a 712% increase of binding (p<0.001), a 348% increase of internalization (/?<0.001), and a 111% increase of degradation (p<0.001) ( Figure 2 ).
PMB was added in increasing amounts (0-1,000 /xg/ml medium) to HepG2 cells incubated with a constant amount of ^I-LDL (5.33 fig LDL protein/ml medium). As shown in Figure 3 , the uptake of ^I-LDL increased with increasing amounts of PMB in a dosedependent manner. At a concentration greater than 800 The time course for uptake and degradation of LDL in the presence of PMB (100 /xg/ml medium) is shown in Figure 4 . There was always a much higher uptake of LDL in the presence of PMB than in the absence of PMB at any time point. The uptake of LDL by the cells sharply increased until the fourth hour of incubation and then decreased with time. The degradation of LDL increased in a linear manner during the whole 24-hour period of incubation at this concentration. This suggests that bound LDL was rapidly internalized and subsequently degraded in the cells.
To elucidate whether PMB was complexed with 125 I-LDL before processing of LDL by the cells, the following experiment was done. PMB was mixed with 125 I-LDL (the ratio of PMB to 125 I-LDL in micrograms per microgram was -100). Then the mixture was incubated for 30 minutes at 37°C followed by dialysis against 0.9% NaCl containing 1 mM EDTA (pH 7.4) (1,000 ml x2) for 24 hours using a dialysis bag with a molecular weight cutoff of 12,000-14,000 to dialyze away free PMB (molecular weight, 1,000). This preparation of the 125 I-LDL-PMB complex (5.33 ^tg LDL protein/ml medium) was added to the cells and compared with dialyzed 125 I-LDL (control) for a 4-hour uptake and degradation assay. As shown in Figure 5 , the 125 I-LDL-PMB complex caused a 236% increase in uptake (/?<0.001) and an 80% increase in degradation (p<0.001) of To clarify whether PMB-induced increases in the uptake and degradation of LDL occur by means of stimulating the LDL receptor-mediated pathway in HepG2 cells, the following experiment was carried out.
A monoclonal anti-LDL receptor antibody, which blocks the LDL receptor-mediated uptake, 14 was added to the cells. The results showed that complete suppression of the LDL receptor-mediated uptake of ^I-LDL by the antibody occurred at an antibody concentration of 4-6 n.gjml medium (data not shown). Both the uptake and degradation of 125 I-LDL in the presence of PMB (500 jig/ml medium) were not affected despite the increasing concentration of antibody to as much as 10 jig/ml medium ( Figure 6 ). This suggests that little if any LDL was processed through the LDL receptor-mediated pathway in the presence of PMB.
Polymyxin B-Mediated Uptake and Degradation of Low Density Lipoprotein Are Dependent on the Presence of Ca in the Medium
The results shown in Figure 7 indicate that the PMB-mediated uptake and degradation of LDL are dependent on the presence of Ca 2+ in the medium. The uptake and degradation of LDL decreased with increasing concentrations of EDTA in the medium. The presence of 4 mM EDTA caused a 19% decrease in the uptake and a 77% decrease in the degradation of I-LDL. The presence of 10 mM EDTA caused a 56% decrease in the uptake and a 92% decrease in the degradation of 125 I-LDL.
Effects of Chloroquine and Colchicine Treatment on the Polymyxin B-Mediated Processing of Low Density Lipoprotein in HepG2 Cells
The roles of microtubules and lysosomes in the PMB-mediated processing of LDL were determined by studying the effects of chloroquine, a general inhibitor 10 of lysosomal hydrolysis, 16 and colchicine, an inhibitor of microtubular polymerization, 17 on the metabolism of I-LDL in the presence of PMB (100 /ig/ml medium) by HepG2 cells. As shown in Table 1 , the addition of chloroquine (50 fiM) caused a 54% increase in the uptake and an 85% reduction in the degradation of I-LDL (p<0.001). At 100 (iM, chloroquine had no further effect on the uptake of 125 I-LDL but inhibited its degradation to an even higher extent (95%). Colchicine also inhibited the degradation of 125 I-LDL. When tested at 1 fiM, colchicine caused a 45% increase in the uptake of 125 I-LDL and a 49% reduction in its degradation (p<0.001). This suggests that the PMB-mediated LDL uptake occurs through an endocytotic pathway, followed by lysosomal hydrolysis. 
FIGURE 6. Line plot of effects of a monoclonal anti-low density lipoprotein (LDL) receptor antibody on polymyxin B (PMB)-mediated uptake and degradation of LDL in HepG2 cells. Increasing amounts of an anti-LDL receptor antibody were added to the dishes. Then l25 I-LDL (5.33 /Jg LDL protein/ml medium) with PMB (500 ug/ml medium) was added to the dishes for a 24-hour uptake and degradation assay as described in "Methods." • -• shows LDL uptake, and
TABLE 1. Effects of ChloroqnJne and Colchicine on Polymyiin B-Medlated Uptake and Degradation of Low Density Lipoprotein in HepG2 Cells
Effects of Pronase, Trypsin, and PhosphoUpase C on the Pofymyxin B-Mediated Processing of Low Density Lipoprotein in HepG2 Cells
To determine whether the PMB-mediated binding of LDL to HepG2 cells was dependent on binding sites containing protein or phospholipid moieties, the following experiments were done. The cells were pretreated with pronase, trypsin, or phospholipase C for 30 minutes at 37°C. The pretreatment was stopped by washing the cells once with RPMI-1640 containing 10% FCS and twice with PBS. The treated cells were then incubated with PMB (100 /xg/ml medium) and 125 I-LDL (5.33 /ig LDL protein/ml medium) for a 4-hour uptake and degradation assay. The results are shown in Table 2 and indicate that the PMB-mediated processing of LDL was sensitive to phospholipase C, mildly sensitive to pronase, and relatively resistant to trypsin treatment. As shown in Table 2 , pretreatment of the cells with 10 ^tg trypsin/ml medium caused a 3% reduction in the uptake and a 28% reduction in the degradation of 
Pofymyxin B-Mediated Processing of Low Density Lipoprotein Also Occurs in Extrahepatic Cells
We also determined whether the PMB-mediated processing of LDL occurred in extrahepatic cells. The results shown in Table 3 indicate that the PMB-medi- Pronase, trypsin, or phospholipase C was added to the dishes for a 30-minute preincubation at 37°C. Then the dishes were washed once with RPMI-1640 containing 10% fetal calf serum and twice with phosphate-buffered saline. After that RPMI-1640 (1 ml/dish) containing 0.5% human serum albumin, 123 I-low density lipoprotein (LDL) (5.33 /ig LDL protein/ml medium), and polymyxin B (100 /ig/ml medium) were added to each dish for a 4-hour uptake and degradation assay as described in "Methods." All values are mean±SD of two dishes. Numbers in parentheses are percentages of control values.
The medium was changed to 1 ml RPMI-1640 containing 0.5% human serum albumin (HSA) (pH 7.4) and polymyxin B (PMB) for a 24-hour preincubation. Then the dishes were washed once with RPMI-1640 containing 0.5% HSA and twice with phosphatebuffered saline. After that 1 ml RPMI-1640 containing 0.5% HSA with l25 I-low density lipoprotein (LDL) (533 fig LDL protein/ml medium) was added to each dish for a 4-hour uptake and degradation assay in the presence (100 /ig/ml medium) or absence of PMB as described in "Methods." Values are mean±SD of two dishes. Numbers in parentheses are percentages of control values. ated enhancement of the cellular catabolism of LDL also occurs in human FBs, bovine SMCs, and bovine ECs. This suggests that the PMB-enhanced cellular uptake of LDL is a general cellular phenomenon.
Effect of Pretreatment of HepG2 Cells With Polymyxin B on Subsequent Low Density Lipoprotein Uptake and Degradation
To elucidate whether pretreatment of the cells with PMB had an effect on the subsequent PMB-mediated uptake and degradation of LDL in HepG2 cells, they were preincubated with PMB for 24 hours. The cells I-low density lipoprotein (LDL) (5.33 n% LDL protein/ml medium) were added to the dishes for a 4-hour uptake and degradation assay as described in "Methods." Values are mean±SD of two to four dishes. Numbers in parentheses are percentages of control values.
were then washed once with RPMI-1640 containing 0.5% HSA and twice with PBS. After that, 125 I-LDL (5.33 /xg LDL protein/ml medium) with or without PMB was added to the dishes for a 4-hour uptake and degradation assay. Pretreatment of the cells with PMB inhibited subsequent LDL uptake and degradation in the absence of PMB and also inhibited PMB-mediated uptake and degradation of LDL in HepG2 cells (Table  4) . Pretreatment of the cells with 500 /ig PMB/ml medium for 24 hours caused a 67% reduction in the uptake (/?<0.005) and 95% reduction in the degradation 
Polymyxin B-Enhanced Uptake of Low Density Lipoprotein Does Not Induce Cholesterol Esterification
One of the consequences of LDL receptor-mediated cellular LDL catabolism is the activation of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT), 18 an enzyme that esterifies cholesterol. An LDL-induced increase in cellular cholesterol esterification occurs merely after uptake of LDL via the LDL receptor. 19 The following experiment was undertaken to study whether PMB by itself affected cholesterol esterification and whether uptake of PMB-LDL increased cholesterol esterification cholesterol esterification (p>0.05). The addition of 500 fig PMB/ml medium resulted in a 55% reduction of basal cholesterol esterification (p<0.025) and a 47% reduction of stimulated cholesterol esterification (p<0.025), which may indicate that PMB at higher concentrations, once inside the cell, can act as an ACAT inhibitor. These data thus show that PMB-mediated cellular uptake of LDL does not lead to increased cholesterol esterification and does not occur through the LDL receptor pathway.
Discussion
Polymyxins, which are polycationic antibiotics, are relatively simple basic peptides with molecular weights of about l.OOO.
1 PMB itself is a mixture of PMB] and PMB2. PMB has surface-active amphipathic properties. Thus, it contains both lipophilic and lipophobic groups within the molecule. PMB has many biologic effects. It interacts strongly with phospholipids and penetrates into and disrupts the structure of cell membranes. 1 Once bacteria sensitive to PMB come into contact with it, the permeability of the bacterial membranes changes immediately. PMB inactivates endotoxins 2 by binding to the lipid A portion of endotoxins (the lipoporysaccharide of the outer membrane of Gram-negative bacteria) and blocks many of the biologic activities of endotoxins.
To our knowledge, this study is the first to present the effects of PMB on cellular LDL processing. The present experiments demonstrate that when a suitable concentration of PMB is used, it dramatically increases the binding, internalization, and subsequent degradation of LDL by HepG2 cells. This cell line is a highly differentiated human hepatoma cell line. Because about two thirds of the LDL is catabolized in the liver in the hepatocytes, it is relevant to study hepatocytic uptake of LDL. However, PMB caused similar changes in human FBs, bovine SMCs, and bovine ECs, showing that the effects of PMB on LDL uptake are not limited to liver cells.
PMB-mediated uptake of LDL by HepG2 cells was shown to occur in a dose-and time-dependent manner. PMB also greatly enhanced the degradation of LDL by HepG2 cells when PMB concentrations were 50-200 fig/M medium but decreased LDL degradation by the cells at higher PMB concentrations, presumably reflecting the inhibitory effects of PMB on lysosomal enzymes. Our study thus indicates that cell surface-bound LDL is rapidly internalized and subsequently degraded by HepG2 cells in the presence of PMB.
PMB-mediated uptake and degradation of LDL did not seem to be dependent on the LDL receptor, as the PMB-stimulated uptake and degradation of LDL were not affected by high concentrations of an anti-LDL receptor antibody. Thus, this suggests that little if any LDL was processed through the LDL receptor-mediated pathway in the presence of PMB. However, there is a slight possibility that PMB alters LDL, so that the PMB-LDL complex can still bind to the LDL receptor but that the binding is not blocked by the anti-LDL receptor antibody. Another characteristic of PMB-mediated LDL uptake was that it did not cause increased cholesterol esterification, which occurs when LDL is taken up through the LDL receptor. However, higher concentrations of PMB led to a decreased cholesterol esterification and a decreased degradation of ^I-LDL, which may suggest that PMB in high concentrations, once inside the cell, could be a general inhibitor of ACAT and lysosomal enzymes.
Like the LDL receptor-mediated processing of LDL, the PMB-mediated uptake of LDL was also inhibited by the addition of EDTA. This suggests that the PMBmediated uptake of LDL is dependent on the presence of divalent cations, presumably Ca 2+ , in the medium. Colchicine also inhibited the PMB-mediated catabolism of LDL, which suggests that transport through an endocytotic pathway is involved. Degradation of PMB-LDL presumably occurs in lysosomes, as chloroquine inhibited the PMB-mediated degradation of LDL. The demonstration that the PMB-mediated processing of LDL is sensitive to phospholipase C and mildly sensitive to pronase indicates that the binding sites are phospholipid-protein complexes.
A 24-hour pretreatment of HepG2 cells with PMB led to a decreased subsequent processing of LDL by the cells in both the presence and absence of PMB. This may be explained by a nonspecific cytotoxic effect of PMB that is not complexed with LDL. The nature of the binding sites for the PMB-mediated processing of LDL is uncertain. Because the structure of PMB contains lipophilic groups, it is reasonable to speculate that PMB complexes with LDL and that the PMB-LDL complex then enters into the cells by an endocytotic pathway after binding to the cell membrane. The fact that dialyzed 125 I-LDL-PMB retained the effect supports this speculation. Recently, Bysani et al 20 demonstrated that PMB specifically binds to rat alveolar macrophages and monocytes. It is not clear whether these binding sites are the same as those in this study, which mediate the PMB-enhanced uptake of LDL, but the former seem to occur only in the macrophage system and are also very sensitive to trypsin.
From the present study, our data show that the PMB-mediated uptake of LDL has some features similar to the LDL receptor-mediated pathway, i.e., Ca 2+ dependency, the involvement of the endocytotic pathway in the internalization process, and the occurrence of degradation in lysosomes. The PMB-mediated LDL uptake is, however, more effective and does not cause an increased cholesterol esterification in the cells. Future studies will reveal more details of the intracellular trafficking of the PMB-LDL complex and the type of mechanism by which PMB-LDL binds to the cell surface. Experiments already carried out (W. Liao and C.-H. Florin, unpublished data) show that PMB cationizes LDL. Presumably, then, the positively charged LDL interacts with negative charges on the cellular plasma membrane, which causes an enhanced uptake and degradation of LDL by the cells.
